CD34 and Cirrhosis: The reference data showed a trend toward worsening of the CP and Model of End-stage Liver Disease (MELD) scores for the historical control group, whereas the transplant group exhibited delayed disease progression, suggesting the efficacy of CD34+ cell therapy in preventing cirrhosis progression and improving liver reserve function.